112 related articles for article (PubMed ID: 31295488)
1. Investigating the oxidative refolding mechanism of Cripto-1 CFC domain.
Iaccarino E; Sandomenico A; Corvino G; Focà G; Severino V; Russo R; Caporale A; Raimondo D; D'Abramo M; Alba J; Chambery A; Ruvo M
Int J Biol Macromol; 2019 Sep; 137():1179-1189. PubMed ID: 31295488
[TBL] [Abstract][Full Text] [Related]
2. The CRIPTO/FRL-1/CRYPTIC (CFC) domain of human Cripto. Functional and structural insights through disulfide structure analysis.
Foley SF; van Vlijmen HW; Boynton RE; Adkins HB; Cheung AE; Singh J; Sanicola M; Young CN; Wen D
Eur J Biochem; 2003 Sep; 270(17):3610-8. PubMed ID: 12919325
[TBL] [Abstract][Full Text] [Related]
3. Structure-based design of small bicyclic peptide inhibitors of Cripto-1 activity.
Iaccarino E; Calvanese L; Untiveros G; Falcigno L; D'Auria G; Latino D; Sivaccumar JP; Strizzi L; Ruvo M; Sandomenico A
Biochem J; 2020 Apr; 477(8):1391-1407. PubMed ID: 32215602
[TBL] [Abstract][Full Text] [Related]
4. Structural insights into the interaction between the Cripto CFC domain and the ALK4 receptor.
Calvanese L; Saporito A; Oliva R; D' Auria G; Pedone C; Paolillo L; Ruvo M; Marasco D; Falcigno L
J Pept Sci; 2009 Mar; 15(3):175-83. PubMed ID: 19035567
[TBL] [Abstract][Full Text] [Related]
5. Cripto stabilizes GRP78 on the cell membrane.
Kouznetsova VL; Hu H; Teigen K; Zanetti M; Tsigelny IF
Protein Sci; 2018 Mar; 27(3):653-661. PubMed ID: 29226519
[TBL] [Abstract][Full Text] [Related]
6. Solution structure of mouse Cripto CFC domain and its inactive variant Trp107Ala.
Calvanese L; Saporito A; Marasco D; D'Auria G; Minchiotti G; Pedone C; Paolillo L; Falcigno L; Ruvo M
J Med Chem; 2006 Nov; 49(24):7054-62. PubMed ID: 17125258
[TBL] [Abstract][Full Text] [Related]
7. Conformational features and binding affinities to Cripto, ALK7 and ALK4 of Nodal synthetic fragments.
Calvanese L; Sandomenico A; Caporale A; Focà A; Focà G; D'Auria G; Falcigno L; Ruvo M
J Pept Sci; 2015 Apr; 21(4):283-93. PubMed ID: 25588905
[TBL] [Abstract][Full Text] [Related]
8. Chemical synthesis, structural modeling, and biological activity of the epidermal growth factor-like domain of human cripto.
Lohmeyer M; Harrison PM; Kannan S; DeSantis M; O'Reilly NJ; Sternberg MJ; Salomon DS; Gullick WJ
Biochemistry; 1997 Apr; 36(13):3837-45. PubMed ID: 9092813
[TBL] [Abstract][Full Text] [Related]
9. Development of conformational antibodies targeting Cripto-1 with neutralizing effects in vitro.
Focà G; Iaccarino E; Focà A; Sanguigno L; Untiveros G; Cuevas-Nunez M; Strizzi L; Leonardi A; Ruvo M; Sandomenico A
Biochimie; 2019 Mar; 158():246-256. PubMed ID: 30703478
[TBL] [Abstract][Full Text] [Related]
10. Subtractive hybridization identifies chick-cripto, a novel EGF-CFC ortholog expressed during gastrulation, neurulation and early cardiogenesis.
Colas JF; Schoenwolf GC
Gene; 2000 Sep; 255(2):205-17. PubMed ID: 11024280
[TBL] [Abstract][Full Text] [Related]
11. Antibody blockade of the Cripto CFC domain suppresses tumor cell growth in vivo.
Adkins HB; Bianco C; Schiffer SG; Rayhorn P; Zafari M; Cheung AE; Orozco O; Olson D; De Luca A; Chen LL; Miatkowski K; Benjamin C; Normanno N; Williams KP; Jarpe M; LePage D; Salomon D; Sanicola M
J Clin Invest; 2003 Aug; 112(4):575-87. PubMed ID: 12925698
[TBL] [Abstract][Full Text] [Related]
12. PGAP6, a GPI-specific phospholipase A2, has narrow substrate specificity against GPI-anchored proteins.
Lee GH; Fujita M; Nakanishi H; Miyata H; Ikawa M; Maeda Y; Murakami Y; Kinoshita T
J Biol Chem; 2020 Oct; 295(42):14501-14509. PubMed ID: 32816994
[TBL] [Abstract][Full Text] [Related]
13. Chemical synthesis of mouse cripto CFC variants.
Marasco D; Saporito A; Ponticelli S; Chambery A; De Falco S; Pedone C; Minchiotti G; Ruvo M
Proteins; 2006 Aug; 64(3):779-88. PubMed ID: 16752415
[TBL] [Abstract][Full Text] [Related]
14. New Anti-Nodal Monoclonal Antibodies Targeting the Nodal Pre-Helix Loop Involved in Cripto-1 Binding.
Focà A; Sanguigno L; Focà G; Strizzi L; Iannitti R; Palumbo R; Hendrix MJ; Leonardi A; Ruvo M; Sandomenico A
Int J Mol Sci; 2015 Sep; 16(9):21342-62. PubMed ID: 26370966
[TBL] [Abstract][Full Text] [Related]
15. A compound-based computational approach for the accurate determination of hot spots.
Wang L; Hou Y; Quan H; Xu W; Bao Y; Li Y; Fu Y; Zou S
Protein Sci; 2013 Aug; 22(8):1060-70. PubMed ID: 23776011
[TBL] [Abstract][Full Text] [Related]
16. Hematopoietic stem cells are regulated by Cripto, as an intermediary of HIF-1α in the hypoxic bone marrow niche.
Miharada K; Karlsson G; Rehn M; Rörby E; Siva K; Cammenga J; Karlsson S
Ann N Y Acad Sci; 2012 Aug; 1266():55-62. PubMed ID: 22901256
[TBL] [Abstract][Full Text] [Related]
17. Recombinant humanized Fab fragments targeting the CFC domain of human Cripto-1.
Sandomenico A; Selis F; Sivaccumar JP; Olimpieri P; Iaccarino E; Cicatiello V; Cantile M; Sanna R; Leonardi A; De Falco S; Ruvo M
Biochem Biophys Res Commun; 2024 Jan; 694():149417. PubMed ID: 38150919
[TBL] [Abstract][Full Text] [Related]
18. Role of the EGF-CFC gene cripto in cell differentiation and embryo development.
Minchiotti G; Parisi S; Liguori GL; D'Andrea D; Persico MG
Gene; 2002 Apr; 287(1-2):33-7. PubMed ID: 11992720
[TBL] [Abstract][Full Text] [Related]
19. Nodal-dependent Cripto signaling promotes cardiomyogenesis and redirects the neural fate of embryonic stem cells.
Parisi S; D'Andrea D; Lago CT; Adamson ED; Persico MG; Minchiotti G
J Cell Biol; 2003 Oct; 163(2):303-14. PubMed ID: 14581455
[TBL] [Abstract][Full Text] [Related]
20. Cripto: a tumor growth factor and more.
Adamson ED; Minchiotti G; Salomon DS
J Cell Physiol; 2002 Mar; 190(3):267-78. PubMed ID: 11857442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
